Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Pulmocide Raises $30.4M for Clinical Development of Inhaled Respiratory Drugs

Pulmocide raised $30.4 million in a Series B round of financing to support the early clinical development of its ...

Forward this item to a colleague:


(Separate multiple addresses by commas)